Rising Threat: Confronting Superbugs in Modern Healthcare
Zosurabalpin: A Potential Breakthrough in Antibiotic Development
Q1: What is Zosurabalpin?
A: Zosurabalpin is a new class of antibiotic developed by Roche. It shows promise in killing drug-resistant strains of carbapenem-resistant Acinetobacter baumannii (CRAB), a superbug.
Q2: Why is CRAB a concern?
A: CRAB is highly resistant to existing antibiotics, causing severe hospital-acquired infections. It’s a priority-1 critical pathogen due to its drug-resistance and impact on public health.
Q3: How does Zosurabalpin work?
A: It blocks the transport of bacterial lipopolysaccharide, leading to toxin build-up and death of CRAB cells.
Q4: What is the current stage of Zosurabalpin’s development?
A: The drug has shown positive results in animal studies and is now undergoing human clinical trials to test safety, tolerability, and effectiveness.
Q5: Why is the development of new antibiotics like Zosurabalpin significant?
A: With rising antimicrobial resistance (AMR), new antibiotics are crucial for treating multidrug-resistant bacteria. Zosurabalpin could fill a major gap in the fight against AMR.
SRIRAM’s
Share:
Get a call back
Fill the below form to get free counselling for UPSC Civil Services exam preparation
